| The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution O Rozenblatt-Rosen, A Regev, P Oberdoerffer, T Nawy, A Hupalowska, ... Cell 181 (2), 236-249, 2020 | 403 | 2020 |
| Regenerative lineages and immune-mediated pruning in lung cancer metastasis AM Laughney, J Hu, NR Campbell, SF Bakhoum, M Setty, VP Lavallée, ... Nature medicine 26 (2), 259-269, 2020 | 325 | 2020 |
| Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer JM Chan, A Quintanal-Villalonga, VR Gao, Y Xie, V Allaj, O Chaudhary, ... Cancer cell 39 (11), 1479-1496. e18, 2021 | 211 | 2021 |
| HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ... Cancer discovery 10 (5), 674-687, 2020 | 199 | 2020 |
| Resistance to TRK inhibition mediated by convergent MAPK pathway activation E Cocco, AM Schram, A Kulick, S Misale, HH Won, R Yaeger, P Razavi, ... Nature medicine 25 (9), 1422-1427, 2019 | 183 | 2019 |
| EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer F Sanchez-Vega, JF Hechtman, P Castel, GY Ku, Y Tuvy, H Won, CJ Fong, ... Cancer discovery 9 (2), 199-209, 2019 | 136 | 2019 |
| Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity A Chow, S Schad, MD Green, MD Hellmann, V Allaj, N Ceglia, G Zago, ... Cancer Cell 39 (7), 973-988. e9, 2021 | 122 | 2021 |
| Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer K Suzawa, M Offin, D Lu, C Kurzatkowski, M Vojnic, RS Smith, JK Sabari, ... Clinical Cancer Research 25 (4), 1248-1260, 2019 | 113 | 2019 |
| Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements AM Schram, I Odintsov, M Espinosa-Cotton, I Khodos, WJ Sisso, ... Cancer Discovery 12 (5), 1233-1247, 2022 | 91 | 2022 |
| Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy RB Holmgaard, A Brachfeld, B Gasmi, DR Jones, M Mattar, T Doman, ... Oncoimmunology 5 (7), e1151595, 2016 | 70 | 2016 |
| Establishing and maintaining an extensive library of patient-derived xenograft models M Mattar, CR McCarthy, AR Kulick, B Qeriqi, S Guzman, E De Stanchina Frontiers in oncology 8, 19, 2018 | 51 | 2018 |
| NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors R Somwar, NE Hofmann, B Smith, I Odintsov, M Vojnic, I Linkov, A Tam, ... Communications biology 3 (1), 776, 2020 | 45 | 2020 |
| MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions H Sato, AJ Schoenfeld, E Siau, YC Lu, H Tai, K Suzawa, D Kubota, ... Clinical Cancer Research 26 (12), 2932-2945, 2020 | 42 | 2020 |
| The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer A Chow, FZ Uddin, M Liu, A Dobrin, BY Nabet, L Mangarin, Y Lavin, ... Immunity 56 (1), 93-106. e6, 2023 | 41 | 2023 |
| The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions I Odintsov, AJW Lui, WJ Sisso, E Gladstone, Z Liu, L Delasos, RI Kurth, ... Clinical Cancer Research 27 (11), 3154-3166, 2021 | 36 | 2021 |
| Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade JA Pai, MD Hellmann, JL Sauter, M Mattar, H Rizvi, HJ Woo, N Shah, ... Cancer Cell 41 (4), 776-790. e7, 2023 | 34 | 2023 |
| Patient derived tumor xenograft models: promise, potential and practice R Uthamanthil, P Tinkey, E De Stanchina Academic Press, 2016 | 27 | 2016 |
| Therapeutic potential of NTRK3 inhibition in desmoplastic small round cell tumor K Ogura, R Somwar, J Hmeljak, H Magnan, R Benayed, ... Clinical Cancer Research 27 (4), 1184-1194, 2021 | 23 | 2021 |
| MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers. R Somwar, R Smith, T Hayashi, K Ishizawa, A Snyder Charen, I Khodos, ... Journal of Clinical Oncology 34 (15_suppl), 9068-9068, 2016 | 22 | 2016 |
| Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers I Odintsov, MS Mattar, AJW Lui, M Offin, C Kurzatkowski, L Delasos, ... Journal of Thoracic Oncology 16 (7), 1149-1165, 2021 | 20 | 2021 |
